Skip to main content


September 29, 2020

Intranasal esketamine is a safe and effective treatment for Treatment-Resistant Depression (TRD).  Spravato is approved by the US-FDA for the treatment of patients with Major Depressive Disorder who have not responded or are intolerant of two antidepressant treatments.  Health professionals provide intranasal esketamine treatment at the UNC Outpatient Clinic at Vilcom Center, located on Weaver-Dairy … Continued

Affective Neuroscience Track Description 2022-2023 

September 21, 2021

Affective Neuroscience Track Description 2022-2023    Track Overview:     Despite the success of evidence-based psychotherapy for mood disorders and the advent of FDA-cleared transcranial magnetic stimulation (TMS) and ketamine, a significant fraction of patients does not recover and is considered “treatment-resistant.” Helping this segment requires state-of-the art care driven by innovative research for the individualization and augmentation of today’s treatments. The UNC … Continued

Interventional Psychiatry

January 24, 2020

Recent advances in pharmacology and neuromodulation have led to the development of novel treatments for neuropsychiatric disorders. These highly specialized interventions are now called Interventional Psychiatry services. The UNC Department of Psychiatry currently provides Interventional Psychiatry services to patients, including Intranasal Esketamine (Spravato), Brexanolone Infusion, and Transcranial Magnetic Stimulation (TMS). These new therapies treatments complement … Continued